DealsAug 12, 2026, 04:11 PM
Royalty Pharma Funds Zealand Pharma with $100M for Rusfertide Royalties
AI Summary
Royalty Pharma announced a $100 million funding agreement with Zealand Pharma, acquiring economic interests related to rusfertide, a potential first-in-class therapy for polycythemia vera. The funding will be disbursed in two tranches, with $50 million upfront and the remainder on the first anniversary. Royalty Pharma will receive a 1% royalty on global net sales of rusfertide, while Zealand Pharma retains a 0.25% royalty on sales exceeding $1.5 billion. The U.S. FDA has set a PDUFA goal date for rusfertide's New Drug Application in Q3 2026, with Takeda handling global commercialization.
Key Highlights
- Royalty Pharma provided $100 million in funding to Zealand Pharma.
- Funding is in exchange for Zealand Pharma’s economic interests related to rusfertide.
- $50 million was paid upon closing, with the remaining $50 million due on the first anniversary.
- Royalty Pharma acquires rights to a 1% royalty on future global net sales of rusfertide.
- Zealand Pharma retains a 0.25% royalty on annual net global sales exceeding $1.5 billion.
- Royalty Pharma retains a 0.75% royalty on sales above $1.5 billion.
- Rusfertide's US FDA PDUFA goal date for NDA is set for Q3 2026.
- Takeda will be responsible for the global commercialization of rusfertide.
Price Impact
More from RPRX